JS212

JS212 is a bispecific antibody-drug conjugate (ADC) developed to target both the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3). It combines a humanized bispecific antibody that binds simultaneously to EGFR and HER3, two proteins frequently overexpressed in various tumor types, including lung cancer, breast cancer, and head and neck cancer. By targeting both receptors, JS212 aims to enhance antitumor efficacy compared to monospecific ADCs and potentially overcome resistance mechanisms associated with single-target therapies. The drug is being developed by Shanghai Junshi Biosciences in collaboration with BioDlink for manufacturing support. As of May 2025, it has received Investigational New Drug (IND) approval from China's National Medical Products Administration for clinical evaluation in advanced malignant solid tumors[1][2][3][4][9].